Clinical Trial Update: Study of the Combination Dostarlimab With Niraparib In Patients With Penile Carcinoma [Phase 2]

View source ↗

Summary

This clinical trial update notes a Phase 2 study evaluating the combination of dostarlimab and niraparib in penile cancer, currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Penile Cancer

Drugs mentioned

• JEMPERLI (DOSTARLIMAB)
• Zejula (Niraparib)

Snippet

Sponsor: H. Lee Moffitt Cancer Center and Research Institute | Conditions: Penile Carcinoma | Phase 2 | Status: RECRUITING